Journal of Atoms and Molecules

Transcription

1 Research Article Journal of Atoms and Molecules An International Online Journal ISSN A NOVEL RP-HPLC METHOD FOR THE QUANTIFICATION OF RUXOLITINIB IN FORMULATIONS P.V.V. Satyanarayana*, Alavala Siva Madhavi Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh, India Received on: Revised on: Accepted on: Abstract: A simple, precise and accurate RP-HPLC method was developed and validated for rapid assay of Ruxolitinib in tablet dosage form. Isocratic elution at a flow rate of 1ml/min was employed on a symmetry Chromosil C18 (250x4.6mm, 5µm in particle size) at ambient temperature. The mobile phase consisted of Acetonitrile: Water: Tetra Hydro Furan (THF) 60:30:10% (V/V/V). The UV detection wavelength was 227nm and 20µl sample was injected. The retention time for Ruxolitinib was 4.28min. The percentage RSD for precision and accuracy of the method was found to be less than 2%. The method was validated as per the ICH guidelines. The method was successfully applied for routine analysis of Ruxolitinib in tablet dosage form and bulk drug. Key Words: Ruxolitinib, RP-HPLC, UV detection, recovery, precise, 227 nm Introduction: * Corresponding author PVV Satyanarayana, sivamadhavi@rocketmail.com Ruxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It is also being investigated for the treatment of other types of cancer and for plaque psoriasis. It is a Janus kinase inhibitor with selectivity for subtypes 1 and 2 of this enzyme.the phase III Controlled Myelofibrosis Study with Oral JAK Innhibitor-I (COMFORT-I) and COMFORT- II trials showed significant benefits by All rights reserved

2 Jamonline / 2(2); 2012 / reducing spleen size, relieving debilitating symptoms, and improving overall survival. In November 2011, ruxolitinib was approved by the U.S. Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis based on results of the COMFORT-I and COMFORT-II Trials Apparatus A Series HPLC system PEAK LC7000 isocratic HPLC with PEAK 7000 delivery system, Rheodyne manual sample injector with switch (77251), Analytical column Chromosil C mm, Electronic balance-denver (SI234), manual Rheodyne injector with a 20 µl loop was used for the injection of sample. PEAK LC software was used. UV 2301 SPECTROPHOTOMETER was used to determine the wavelength of maximum absorbance Determination of wavelength of maximum absorbance Figure 1: Stricture of Ruxolitinib Ruxolitinib has been assigned to pregnancy category C by the FDA. In animal studies, treatment with ruxolitinib resulted in an increase in late resorptions and reduced foetal weights at maternally toxic doses. There are no adequate and well controlled studies of ruxolitinib in pregnant women. Ruxolitinib should be used during pregnancy only if the potential benefit outweighs the potential risk to the developing fetus. Experimental: Materials Working standard of Ruxolitinib was obtained from well reputed research laboratories. HPLC grade water, Acetonitrile, THF (tetra hydro furan) was purchased from E. Merck (Mumbai, India). All rights reserved 2011 The standard solutions of Ruxolitinib were scanned in the range of nm against mobile phase as a blank. Ruxolitinib showed maximum absorbance at 277 nm. So the wavelength selected for the determination of Ruxolitinib was 227 nm. Chromatographic equipment and conditions The development and validation of the assay was performed on A Series 200 HPLC system PEAK LC7000 isocratic HPLC with PEAK 7000 delivery system. Rheodyne manual sample injector with switch (77251), Analytical column Chromosil C mm, manual injector rheodyne valve) with 20µL fixed loop, PEAK LC software was used. The mobile phase consisted of Acetonitrile: water: THF 60:30:10(V/V/V). Injections were 224

3 carried out using a 20 µl loop at room temperature ( C) and the flow rate was 1 ml/min. Detection was performed at 227 nm with 10min runtime. Standard and sample solutions A 10 mg amount of Ruxolitinib reference substance was accurately weighed and dissolved in 10 ml mobile phase in a 10 ml volumetric flask to obtain 1000 ppm concentrated solution. From standard solution by the serial dilution we prepared required concentrations of 100 ppm. A composite of 20 tablets was prepared by grinding them to a fine, uniform size powder. 100mg of Ruxolitinib was accurately weighed and quantitatively transferred into a 100 ml volumetric flask. Approximately, 25 ml mobile phase were added and the solution was sonicated for 15 min. The flask was filled to volume with mobile phase, and mixed. After filtration, an amount of the solution was diluted with mobile phase to a concentration of 100 ppm. Method validation Method validation was performed following ICH specifications for specificity, range of linearity, accuracy, precision and robustness. chromatography was monitored by applying the following system suitability tests: capacity factor, tailing factor and theoretical plates. The system suitability method acceptance criteria set in each validation run were: capacity factor >2.0, tailing factor 2.0 and theoretical plates >2500. In all cases, the relative standard deviation (R.S.D) for the analytic peak area for two consecutive injections was < 2.0%. A chromatogram obtained from reference substance solution is presented. System suitability parameters were shown in Table.1. Standard chromatogram was given in Figure.2 Mobile phase Pump mode P H 5.8 Diluents Column Column Temp Wavelength Acetonitrile: Water : THF (60:30:10 (v/v)) Isocratic Mobile phase Zodiac C18 column (250 X 4.6 mm, 5µ) Ambient 227nm Injection Volume 20 µl Results and Discussions: System Suitability Flow rate Run time 1 ml/min 10 minutes Having optimized the efficiency of a chromatographic separation the quality of the Retention Time 4.28 minutes Table 1 System suitability parameters All rights reserved

4 Figure.2 Standard Chromatogram of Ruxolitinib Range of linearity Standard curves were constructed daily, for three consecutive days, using seven standard concentrations in a range of 25, 50, 75, 100, 125 and 150ppm for Ruxolitinib. The linearity of peak area responses versus concentrations was demonstrated by linear least square regression analysis. The linear regression equation was y = x (r= ). Linearity values can shown in Table: 2 All rights reserved

5 Level Conc. of Ruxolinitinib in PPM Peak Area Level Level Level Level Level Level Range 25 ppm to 150 ppm Slope Intercept Correlation Coefficient Table 2: Linearity results of Ruxolitinib Area Concentration Figure 3: Calibration curve of Ruxolitinib Precision To study precision, six replicate standard solutions of Ruxolitinib (100 ppm) were prepared and analyzed using the proposed method. The percent relative standard deviation (% RSD) for peak responses was calculated and it was found to be which is well within the acceptance criteria of not more than 2.0%. Results of intraday and inter day precision studies are shown in Table.3 and Table.4 respectively. All rights reserved

6 Sample Conc. (in ppm) Injection No. Peak Areas RSD (Acceptance Criteria 2.0%) Ruxolitinib Table 3: Intraday Precision Results for Ruxolitinib. Sample Conc. (in ppm) Injection No. Peak Areas RSD (Acceptance Criteria 2.0%) Ruxolitinib Table 4: Inter day Precision Results for Ruxolitinib. Limit of Detection and Limit of Quantification: To determine the Limit of Detection (LOD) sample was dissolved by using Mobile phase and injected until peak was disappeared. After 0.05 ppm dilution Peak was not clearly observed, based on which 0.05ppm is considered as Limit of Detection and Limit of Quantification is 0.16 ppm. Parameter Limit of Quantification Limit of Detection Measured Value 0.16 ppm 0.05ppm Table 5: LOD and LOQ of Ruxolitinib All rights reserved

7 Robustness Typical variations in liquid chromatography conditions were used to evaluate the robustness of the assay method. In this study, the chromatographic parameters monitored were retention time, area, capacity factor, tailing factor and theoretical plates. The robustness acceptance criteria set in the validation were the same established on system suitability test describe above. S.NO Parameter Condition Area % Of Change 1 Standard Standard conditions Mobile phase Acetonitrile : H 2 O : THF (65:25:10) Mobile phase P H Wavelength 222 nm Table 6: Robustness results of Ruxolitinib. Recovery: Recovery test was performed at 3 different concentrations i.e.50ppm, 100ppm, and 150 ppm. Results are given in table.7. Recovery Conc. of sample (ppm) Recovery (ppm) % of recovery 50% % % Table 7: recovery results of Ruxolitinib All rights reserved

8 . S.NO Tablet Dosage Sample conc. Sample estimated % of Drug Estimated in Tablet 1 Jakafi 10mg 100 ppm ppm 99.12% Table.8: Formulation Analysis Conclusion: The proposed method for the assay of Ruxolitinib in tablets or capsules is very simple and rapid. It should be emphasized it is isocratic and the mobile phase do not contain any buffer. The method was validated for specificity, linearity, precision, accuracy and robustness. Although the method could effectively separate the drug from its products, further studies should be performed in order to use it to evaluate the stability of pharmaceutical formulations. References: 1 Shilling, A. D.; Nedza, F. M.; Emm, T.; Diamond, S.; McKeever, E.; Punwani, N.; Williams, W.; Arvanitis, A. et al (2010). "Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans". Drug Metabolism and Disposition38 (11): Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter (2012). "Ruxolitinib". Nature Reviews Drug Discovery11 (2): Mesa, RA (2010). "Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis". IDrugs : the investigational drugs journal13 (6): Pardanani, A.; Tefferi, A. (2011). "Targeting myeloproliferative neoplasms with JAK inhibitors". Current Opinion in Hematology18 (2): 1. 5 Harrison, C.; Kiladjian, J. J.; Al-Ali, H. K.; Gisslinger, H.; Waltzman, R.; Stalbovskaya, V.; McQuitty, M.; Hunter, D. S. et al (2012). "JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis". New England Journal of Medicine366 (9): Verstovsek, S.; Mesa, R. A.; Gotlib, J.; Levy, R. S.; Gupta, V.; Dipersio, J. F.; Catalano, J. V.; Deininger, M. et al (2012). "A Double-Blind, Placebo- All rights reserved

9 Controlled Trial of Ruxolitinib for Myelofibrosis". New England Journal of Medicine366 (9): Tefferi, A. (2012). "Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms". New England Journal of Medicine366 (9): ASCO Annual Meeting 2011: JAK Inhibitor Ruxolitinib Demonstrates Significant Clinical Benefit in Myelofibrosis 9 "FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis" (Press release). Incyte. Retrieved All rights reserved